CLYM Stock Overview
A biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Climb Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$11.55 |
| 52 Week Low | US$2.35 |
| Beta | -0.34 |
| 11 Month Change | -27.70% |
| 3 Month Change | -49.26% |
| 1 Year Change | 18.92% |
| 33 Year Change | -77.45% |
| 5 Year Change | n/a |
| Change since IPO | -80.63% |
Recent News & Updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Shareholder Returns
| CLYM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | 4.0% | 2.2% |
| 1Y | 18.9% | 18.3% | 32.6% |
Return vs Industry: CLYM exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: CLYM underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| CLYM volatility | |
|---|---|
| CLYM Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLYM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLYM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Aoife Brennan | eliemtx.com |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. Fundamentals Summary
| CLYM fundamental statistics | |
|---|---|
| Market cap | US$205.03m |
| Earnings (TTM) | -US$69.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs CLYM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLYM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.12m |
| Earnings | -US$69.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CLYM perform over the long term?
See historical performance and comparison